Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
6 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Calidi Biotherapeutics, Inc.’s names, not what it holds today.
Patents granted
6
6 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against none in 2024 and 2 in 2023
Applications published
9
since 2001, to Dec 31, 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals2
Biotechnology2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
CALIDI BIOTHERAPEUTICS, INC. its own name
named as the applicant on its applications, in US
9 publishedCalidi Biotherapeutics, Inc. its own name
US, as the owner printed on each patent
0 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| May 23, 2023 | 11,655,455 | Enhanced systems for cell-mediated oncolytic viral therapy | Biotechnology | Calidi Biotherapeutics, Inc. |
| Mar 21, 2023 | 11,607,450 | Smallpox vaccine for cancer treatment | Pharmaceuticals | Calidi Biotherapeutics, Inc. |
| Nov 22, 2022 | 11,505,782 | Cell-based vehicles for potentiation of viral therapy | Biotechnology | Calidi Biotherapeutics, Inc. |
| Mar 29, 2022 | 11,285,194 | Combination immunotherapy approach for treatment of cancer | Pharmaceuticals | Calidi Biotherapeutics, Inc. |
| Dec 8, 2020 | 10,857,225 | Smallpox vaccine for cancer treatment | Pharmaceuticals | Calidi Biotherapeutics, Inc. |
| Oct 23, 2018 | 10,105,436 | Smallpox vaccine for cancer treatment | Pharmaceuticals | Calidi Biotherapeutics, Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Aug 24, 2023 | 2023/0265392 | ENHANCED SYSTEMS FOR CELL-MEDIATED ONCOLYTIC VIRAL THERAPY | Biotechnology | CALIDI BIOTHERAPEUTICS, INC. |
| Jun 8, 2023 | 2023/0173062 | SMALLPOX VACCINE FOR CANCER TREATMENT | Pharmaceuticals | CALIDI BIOTHERAPEUTICS, INC. · patent 12,036,278 granted from it |
| Jan 26, 2023 | 2023/0022205 | CELL-BASED VEHICLES FOR POTENTIATION OF VIRAL THERAPY | Pharmaceuticals | CALIDI BIOTHERAPEUTICS, INC. |
| Aug 4, 2022 | 2022/0241388 | COMBINATION IMMUNOTHERAPY APPROACH FOR TREATMENT OF CANCER | Pharmaceuticals | CALIDI BIOTHERAPEUTICS, INC. |
| Feb 18, 2021 | 2021/0046178 | SMALLPOX VACCINE FOR CANCER TREATMENT | Pharmaceuticals | CALIDI BIOTHERAPEUTICS, INC. · patent 11,607,450 granted from it |
| Oct 8, 2020 | 2020/0318073 | CELL-BASED VEHICLES FOR POTENTIATION OF VIRAL THERAPY | Biotechnology | CALIDI BIOTHERAPEUTICS, INC. · patent 11,505,782 granted from it |
| May 7, 2020 | 2020/0140824 | ENHANCED SYSTEMS FOR CELL-MEDIATED ONCOLYTIC VIRAL THERAPY | Biotechnology | CALIDI BIOTHERAPEUTICS, INC. · patent 11,655,455 granted from it |
| Dec 5, 2019 | 2019/0367880 | CELL-BASED VEHICLES FOR POTENTIATION OF VIRAL THERAPY | Biotechnology | CALIDI BIOTHERAPEUTICS, INC. · patent 11,505,782 granted from it |
| Nov 15, 2018 | 2018/0326048 | SMALLPOX VACCINE FOR CANCER TREATMENT | Pharmaceuticals | CALIDI BIOTHERAPEUTICS, INC. · patent 10,857,225 granted from it |
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.